In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Stock analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Arrowhead Pharmaceuticals in a ...

HC Wainwright reaffirmed their buy rating on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) in a research ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a decline, ending the day at $20.76 which represents a decrease of $-0.77 or -3.58% from the prior close of $21.53. The stock opened at $21.23 and ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.53 which represents a slight increase of $1.82 or 9.23% from the prior close of $19.71. The stock opened at $20.05 ...

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms ...

S&P Dow Jones Indices said that Guidewire Software Inc. (GWRE) will replace Arrowhead Pharmaceuticals Inc. (ARWR) in the S&P MidCap ...

Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...